Physician profile
Timothy D Marsho
NPI 1316107196
$4,451.14
in general payments reported to CMS, 2019-2025
29 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $447 · 2021: $304 · 2022: $624 · 2023: $719 · 2024: $899 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $614.36 | 2022-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $407.60 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $384.41 | 2020-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $298.92 | 2022-2025 | Qelbree, Qelbree |
| Neurelis, INC. | $292.00 | 2022-2025 | Valtoco |
| Neos Therapeutics, LP | $262.75 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Pfizer INC. | $255.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $230.17 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Merck Sharp & Dohme LLC | $224.88 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Seqirus USA INC | $170.92 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Ultragenyx Pharmaceutical INC. | $159.19 | 2019-2024 | Crysvita |
| Collegium Pharmaceutical, INC. | $154.29 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $139.66 | 2020-2021 | |
| Kaleo, INC. | $113.79 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $113.17 | 2019-2025 | Doc Band |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $87.57 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.61 | 2020-2022 | |
| Sanofi Pasteur INC. | $68.24 | 2020-2023 | |
| Sobi, INC | $54.77 | 2019-2023 | |
| Shire North American Group INC | $53.32 | 2019 | |
| Verrica Pharmaceuticals INC. | $47.98 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $46.93 | 2025 | Neffy |
| Dermira, INC. | $41.77 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $32.76 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $29.59 | 2022 | |
| Neuronetics, INC. | $25.07 | 2025 | Neurostar Tms Therapy System |
| Modernatx, INC. | $24.68 | 2023 | Moderna Covid-19 Vaccine |
| Alexion Pharmaceuticals, INC. | $20.73 | 2024 | Koselugo |
| Vertical Pharmaceuticals, LLC | $17.78 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Marsho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.